MedTrace Logo

A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer

NCT00584012 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2018-10-19

Study results available
· View outcomes & findings →

Summary

This purpose of this study is to evaluate the use of two medications, docetaxel and lovastatin to determine the highest dose of lovastatin and docetaxel that can be given safely as well as the safety of combining the two drugs and the effect on the subject's tumor. Subjects can have any cancer.

Conditions

Interventions

DRUG

Lovastatin

Given PO

DRUG

Docetaxel

Given IV

Sponsors & Collaborators

  • Susan L Roeder

    lead OTHER

Principal Investigators

  • Susan Roman, DO · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2009-04-30
Completion
2009-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00584012 on ClinicalTrials.gov